Key result
Invasive coronary endotyping in ANOCA is linked to improved angina quality of life in 4 of 6 endotypes.
Why the study?
Does endotype-guided pharmacological therapy improve angina-related health status in patients with ANOCA?
Observational (n=525)
Yes
Does endotype-guided pharmacological therapy improve angina-related health status in patients with ANOCA?
Answers are grounded in this paper and cite their sources.
Invasive coronary endotyping in ANOCA patients guides distinct pharmacological management and is associated with significant improvements in angina-related quality of life for specific endotypes.
BACKGROUND: Invasive coronary functional testing enables the classification of angina with non-obstructive coronary arteries (ANOCA) into distinct endotypes. However, real-world data linking endotype identification to subsequent pharmacological management and patient-reported symptom outcomes remain limited. AIMS: We sought to evaluate the association between coronary endotypes, post-testing pharmacological treatment patterns, and changes in angina-related quality of life in patients with ANOCA in a multicentre real-world registry. METHODS: Consecutive ANOCA patients undergoing invasive coronary functional testing were included. Patients were classified into six endotypes using adenosine- and acetylcholine-based testing. Pharmacological therapy was adjusted at the discretion of the treating physician based on the functional test results. The primary endpoint was a clinically meaningful improvement in angina-related health status, defined as a ≥5-point increase in the 7-item Seattle Angina Questionnaire (SAQ-7) summary score, assessed within each endotype. RESULTS: Among 525 patients, endotype distribution was as follows: normal physiology 10.5%, elevated resting coronary blood flow 8.8%, high resistance 13.9%, compensated high resistance 14.9%, epicardial spasm 33.3%, and microvascular spasm 18.7%. After testing, prescription patterns differed across the endotypes, with increased use of beta blockers, ranolazine, and renin-angiotensin-aldosterone system blockers in coronary microvascular dysfunction endotypes and greater use of non-dihydropyridine calcium channel blockers in vasospastic endotypes. At follow-up, a ΔSAQ-7 summary score ≥5 points was observed in elevated resting flow, high-resistance, compensated high-resistance, and epicardial spasm endotypes (all p<0.001) but not in microvascular spasm or normal physiology. CONCLUSIONS: In this multicentre real-world registry, invasive coronary endotyping was associated with distinct pharmacological management patterns and differential changes in angina-related quality of life across ANOCA endotypes.
No takes yet. Share an insight, caveat, or question.
Farina et al. (2026) conducted an observational in Angina with non-obstructive coronary arteries (ANOCA) (n=525). Invasive coronary endotyping and endotype-guided medical therapy was evaluated on Clinically meaningful improvement in angina-related health status, defined as a ≥5-point increase in the 7-item Seattle Angina Questionnaire (SAQ-7) summary score (p=<0.001). Invasive coronary endotyping in ANOCA patients was associated with distinct pharmacological management and significant improvements in angina-related quality of life in 4 of 6 endotypes (all p<0.001).
Synapse has enriched 10 related papers. Consider them for comparative context: